<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01573273</url>
  </required_header>
  <id_info>
    <org_study_id>00016890</org_study_id>
    <nct_id>NCT01573273</nct_id>
  </id_info>
  <brief_title>Oxytocin in Cocaine Dependence</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stress is likely involved in relapse to cocaine use. This project will investigate the role
      oxytocin may play in the stress response in cocaine-dependent men and women and examine how
      oxytocin may impact brain activity in individuals exposed to cocaine-related cues.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stress is an important predictor of relapse, and targeting stress-activated pathways may lead
      to therapeutic advancements in the treatment of substance use disorders. Oxytocin has been
      shown to promote trust, social bonding, and calmness; however, its potential effects have not
      been explored in cocaine-dependent individuals. Oxytocin receptors have been localized to
      brain regions that are activated by drug-paired cues and preclinical studies have shown that
      oxytocin attenuates the acute and long-term behavioral effects of psychostimulants. However,
      little is known about the role of oxytocin in mediating the affective response to
      cocaine-paired cues and associated neural activity in cocaine-dependent men and women. This
      project is a direct evolution from our previous SCOR-supported research. Our work has
      progressed from characterizing sex/gender differences in response to social stressors and
      cocaine cues in cocaine-dependent men and women, to our on-going work evaluating whether
      stress potentiates cue-induced craving and the impact of hormones on this response. The
      proposed study will investigate the role of oxytocin in the sex/gender differences in stress
      response and craving in cocaine-dependent individuals and preliminarily explore its
      therapeutic potential.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 19, 2017</completion_date>
  <primary_completion_date type="Actual">December 19, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Stress Response TSST</measure>
    <time_frame>Subjects rated stress immediately following a Social Stress task on Day 1 of 3.</time_frame>
    <description>Subjects rated stress levels on a 0-10 Likert Scale where 0 is Not at All and 10 is Extremely so that lower scores indicate lower stress levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Stress Response MRI 1</measure>
    <time_frame>Subjects rated Stress immediately following the first of two MRI scans on Day 2 of 3.</time_frame>
    <description>Subjects rated stress levels on a 0-10 Likert Scale where 0 is Not at All and 10 is Extremely so that lower scores indicate lower stress levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective Stress Response MRI 2</measure>
    <time_frame>Subjects rated stress immediately following the second of two MRI scans on Day 3 of 3.</time_frame>
    <description>Subjects rated stress levels on a 0-10 Likert Scale where 0 is Not at All and 10 is Extremely so that lower scores indicate lower stress levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject Cocaine Craving TSST</measure>
    <time_frame>Subjects rated craving immediately following a Social Stress task on Day 1 of 3.</time_frame>
    <description>Subjects rated craving on a 0-10 Likert Scale where 0 is Not at All and 10 is Extremely so that lower scores indicate lower craving.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Cocaine Craving MRI 1</measure>
    <time_frame>Subjects rated craving immediately following the first of two MRI scans on Day 2 of 3.</time_frame>
    <description>Subjects rated craving on a 0-10 Likert Scale where 0 is Not at All and 10 is Extremely so that lower scores indicate lower craving.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Cocaine Craving MRI 2</measure>
    <time_frame>Subjects rated craving immediately following the second of two MRI scans on Day 3 of 3.</time_frame>
    <description>Subjects rated craving on a 0-10 Likert Scale where 0 is Not at All and 10 is Extremely so that lower scores indicate lower craving.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>TSST Women Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TSST Women Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cocaine-dependent women received intranasal saline prior to completing a Social Stress Task.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI 1 Women Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing the first of two fMRI cue-exposure tasks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI 1 Women Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cocaine-dependent women received intranasal saline prior to completing the first of two fMRI cue-exposure tasks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI 2 Women Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing the second of two fMRI cue-exposure tasks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI 2 Women Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cocaine-dependent women received intranasal saline prior to completing the second of two fMRI cue-exposure tasks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TSST Men Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TSST Men Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cocaine-dependent men received intranasal saline prior to completing a Social Stress Task.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI I Men Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing the first of two fMRI cue-exposure tasks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI I Men Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cocaine-dependent men received intranasal saline prior to completing the first of two fMRI cue-exposure tasks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI 2 Men Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing the second of two fMRI cue-exposure tasks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRI 2 Men Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cocaine-dependent men received intranasal saline prior to completing the second of two fMRI cue-exposure tasks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>intranasal administration, 40 IUs</description>
    <arm_group_label>MRI 1 Women Oxytocin</arm_group_label>
    <arm_group_label>MRI 2 Men Oxytocin</arm_group_label>
    <arm_group_label>MRI 2 Women Oxytocin</arm_group_label>
    <arm_group_label>MRI I Men Oxytocin</arm_group_label>
    <arm_group_label>TSST Men Oxytocin</arm_group_label>
    <arm_group_label>TSST Women Oxytocin</arm_group_label>
    <other_name>pitocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>intranasal administration, 40 IUs</description>
    <arm_group_label>MRI 1 Women Placebo</arm_group_label>
    <arm_group_label>MRI 2 Men Placebo</arm_group_label>
    <arm_group_label>MRI 2 Women Placebo</arm_group_label>
    <arm_group_label>MRI I Men Placebo</arm_group_label>
    <arm_group_label>TSST Men Placebo</arm_group_label>
    <arm_group_label>TSST Women Placebo</arm_group_label>
    <other_name>pitocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Subjects must be able to provide informed consent and function at an intellectual
             level sufficient to allow accurate completion of all assessment instruments.

          2. Subjects must meet DSM-IV criteria for current cocaine dependence (within the past
             three months). While individuals may also meet criteria for abuse of other substances,
             they must not meet criteria for dependence on any other substance (except nicotine)
             within the last 60 days. Alcohol has been known to affect HPA function (Adinoff et
             al., 1991), however to enhance recruitment efforts individuals with alcohol dependence
             or abuse will be included in the study if they do not require medically supervised
             detoxification. Also, due to the high comorbidity of cocaine and marijuana dependence,
             and limited evidence that marijuana use affects HPA function, subjects with marijuana
             dependence will be included.

          3. Subjects must consent to remain abstinent from all drugs of abuse (except nicotine)
             for a three-day period immediately prior to the throughout study procedures.

          4. Subjects must consent to random assignment.

          5. Subjects must consent to participating in study procedures at the ASD and completion
             of two fMRI scans.

        Exclusion Criteria

          1. Women who are pregnant, nursing or of childbearing potential and not practicing an
             effective means of birth control (not including hormonal contraceptives).

          2. Women who are currently taking, or have taken in the past month, oral or other types
             of hormonal contraceptives or hormone replacement therapies.

          3. Women with premenstrual dysphoric disorder who are outside of the follicular phase.

          4. Women who have had a complete hysterectomy or are over 50 over one year
             post-menopausal, as ovarian hormones will be measured in the study.

          5. Subjects with evidence of or a history of significant hematological, endocrine,
             cardiovascular, pulmonary, renal, gastrointestinal, or neurological disease including
             diabetes, as these conditions may affect physiological/subjective responses.
             Neurological exclusions include history of stroke, seizure disorders, multiple
             sclerosis, Parkinson's disease, and Alzheimer's disease.

          6. Subjects with Addison's disease, Cushing's disease or other diseases of the adrenal
             cortex likely to affect hormonal/neuroendocrine status.

          7. Subjects with a history of or current psychotic disorder or bipolar affective disorder
             as these may interfere with subjective measurements.

          8. Subjects with current major depressive disorder or post-traumatic stress disorder as
             these disorders are associated with characteristic changes in stress response.

          9. Subjects receiving synthetic glucocorticoid therapy, any exogenous steroid therapy, or
             treatment with other agents that interfere with hormonal measurements within one month
             of test session.

         10. Subjects taking any mood stabilizers, antipsychotics, benzodiazepines, opiates or
             opiate antagonists because these may affect test response. Subjects taking SSRI's will
             be included.

         11. Subjects with any acute illness or fever. Individuals who otherwise meet study
             criteria will be rescheduled for evaluation for participation.

         12. Subjects whose height to weight ratio would preclude them from fitting comfortably in
             the MRI scanner.

         13. Subjects who are unwilling or unable to maintain abstinence from alcohol and other
             drugs of abuse (except nicotine) for three days prior to the stress task procedure.

         14. Persons with ferrous metal implants or pacemaker since fMRI will be used.

         15. Subjects who are claustrophobic.

         16. Subjects with significant psychiatric or medical problems that would impair
             participation or limit ability to participate in scan.

         17. Subjects who require maintenance or acute treatment with any psychoactive medication
             including anti-seizure medications which could potentially interfere with fMRI.

         18. Subjects meeting DSM-IV criteria for substance dependence (other than nicotine,
             cocaine, alcohol or marijuana) within the past 60 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aimee McRae-Clark, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>April 5, 2012</study_first_submitted>
  <study_first_submitted_qc>April 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2012</study_first_posted>
  <results_first_submitted>December 11, 2018</results_first_submitted>
  <results_first_submitted_qc>March 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2019</results_first_posted>
  <last_update_submitted>March 11, 2019</last_update_submitted>
  <last_update_submitted_qc>March 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Aimee McRae-Clark</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>cocaine</keyword>
  <keyword>substance abuse</keyword>
  <keyword>drug abuse</keyword>
  <keyword>cocaine dependence</keyword>
  <keyword>drug addiction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT01573273/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>112 is the total number of participants randomized. 112 completed the TSST, which was between groups. MRIs were within subjects; 99 completed at least MRI 1. 96 completed MRI's 1 and 2. Data is reported per testing condition.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TSST Women Oxytocin</title>
          <description>Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task.
Oxytocin: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="P2">
          <title>TSST Women Placebo</title>
          <description>Cocaine-dependent women received intranasal saline prior to completing a Social Stress Task.
Saline: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="P3">
          <title>MRI 1 Women Oxytocin</title>
          <description>Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing the first of two fMRI cue-exposure tasks.
Oxytocin: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="P4">
          <title>MRI 1 Women Placebo</title>
          <description>Cocaine-dependent women received intranasal saline prior to completing the first of two fMRI cue-exposure tasks.
Saline: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="P5">
          <title>MRI 2 Women Oxytocin</title>
          <description>Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing the second of two fMRI cue-exposure tasks.
Oxytocin: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="P6">
          <title>MRI 2 Women Placebo</title>
          <description>Cocaine-dependent women received intranasal saline prior to completing the second of two fMRI cue-exposure tasks.
Saline: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="P7">
          <title>TSST Men Oxytocin</title>
          <description>Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task.
Oxytocin: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="P8">
          <title>TSST Men Placebo</title>
          <description>Cocaine-dependent men received intranasal saline prior to completing a Social Stress Task.
Saline: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="P9">
          <title>MRI I Men Oxytocin</title>
          <description>Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing the first of two fMRI cue-exposure tasks.
Oxytocin: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="P10">
          <title>MRI I Men Placebo</title>
          <description>Cocaine-dependent men received intranasal saline prior to completing the first of two fMRI cue-exposure tasks.
Saline: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="P11">
          <title>MRI 2 Men Oxytocin</title>
          <description>Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing the second of two fMRI cue-exposure tasks.
Oxytocin: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="P12">
          <title>MRI 2 Men Placebo</title>
          <description>Cocaine-dependent men received intranasal saline prior to completing the second of two fMRI cue-exposure tasks.
Saline: intranasal administration, 40 IUs</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>TSST : Trier Social Stress Task</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="32"/>
                <participants group_id="P8" count="31"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="32"/>
                <participants group_id="P8" count="31"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>MRI 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="23"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="28"/>
                <participants group_id="P10" count="29"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="23"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="28"/>
                <participants group_id="P10" count="29"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>MRI 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="23"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="27"/>
                <participants group_id="P12" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="23"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="27"/>
                <participants group_id="P12" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>112 is the total number of participants randomized to receive Oxytocin or Placebo prior to the TSST.</population>
      <group_list>
        <group group_id="B1">
          <title>Cocaine- Dependent Women Oxytocin</title>
          <description>Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task on Day 1, and MRI on Day 2 and an MRI on Day 3. The TSST task was between subjects; the MRI tasks were within subjects.</description>
        </group>
        <group group_id="B2">
          <title>Cocaine- Dependent Men Oxytocin</title>
          <description>Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task on Day 1, and MRI on Day 2 and an MRI on Day 3. The TSST task was between subjects; the MRI tasks were within subjects.</description>
        </group>
        <group group_id="B3">
          <title>Cocaine- Dependent Women Placebo</title>
          <description>Cocaine-dependent women received Placebo prior to completing a Social Stress Task on Day 1, and MRI on Day 2 and an MRI on Day 3. The TSST task was between subjects; the MRI tasks were within subjects.</description>
        </group>
        <group group_id="B4">
          <title>Cocaine -Dependent Men Placebo</title>
          <description>Cocaine-dependent men received Placebo prior to completing a Social Stress Task on Day 1, an MRI on Day 2 and an MRI on Day 3. The TSST task was between subjects; the MRI tasks were within subjects.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="31"/>
            <count group_id="B5" value="112"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjective Stress Response TSST</title>
        <description>Subjects rated stress levels on a 0-10 Likert Scale where 0 is Not at All and 10 is Extremely so that lower scores indicate lower stress levels.</description>
        <time_frame>Subjects rated stress immediately following a Social Stress task on Day 1 of 3.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TSST Women Oxytocin</title>
            <description>Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task.
Oxytocin: intranasal administration, 40 IUs</description>
          </group>
          <group group_id="O2">
            <title>TSST Women Placebo</title>
            <description>Cocaine-dependent women received intranasal saline prior to completing a Social Stress Task.
Saline: intranasal administration, 40 IUs</description>
          </group>
          <group group_id="O3">
            <title>TSST Men Oxytocin</title>
            <description>Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task.
Oxytocin: intranasal administration, 40 IUs</description>
          </group>
          <group group_id="O4">
            <title>TSST Men Placebo</title>
            <description>Cocaine-dependent men received intranasal saline prior to completing a Social Stress Task.
Saline: intranasal administration, 40 IUs</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Stress Response TSST</title>
          <description>Subjects rated stress levels on a 0-10 Likert Scale where 0 is Not at All and 10 is Extremely so that lower scores indicate lower stress levels.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.33" spread="3.81"/>
                    <measurement group_id="O2" value="5.28" spread="4.09"/>
                    <measurement group_id="O3" value="2.05" spread="2.34"/>
                    <measurement group_id="O4" value="2.13" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective Stress Response MRI 1</title>
        <description>Subjects rated stress levels on a 0-10 Likert Scale where 0 is Not at All and 10 is Extremely so that lower scores indicate lower stress levels</description>
        <time_frame>Subjects rated Stress immediately following the first of two MRI scans on Day 2 of 3.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MRI 1 Women Oxytocin</title>
            <description>Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing the first of two MRI scans.
Oxytocin: intranasal administration, 40 IUs</description>
          </group>
          <group group_id="O2">
            <title>MRI 1 Women Placebo</title>
            <description>Cocaine-dependent women received intranasal saline prior to completing the first of two MRI scans.
Saline: intranasal administration, 40 IUs</description>
          </group>
          <group group_id="O3">
            <title>MRI 1 Men Oxytocin</title>
            <description>Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing the first of two MRI scans.
Oxytocin: intranasal administration, 40 IUs</description>
          </group>
          <group group_id="O4">
            <title>MRI 1 Men Placebo</title>
            <description>Cocaine-dependent men received intranasal saline prior to completing the first of two MRI scans.
Saline: intranasal administration, 40 IUs</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Stress Response MRI 1</title>
          <description>Subjects rated stress levels on a 0-10 Likert Scale where 0 is Not at All and 10 is Extremely so that lower scores indicate lower stress levels</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="2.34"/>
                    <measurement group_id="O2" value="2.13" spread="2.87"/>
                    <measurement group_id="O3" value="1.75" spread="2.40"/>
                    <measurement group_id="O4" value="2.66" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjective Stress Response MRI 2</title>
        <description>Subjects rated stress levels on a 0-10 Likert Scale where 0 is Not at All and 10 is Extremely so that lower scores indicate lower stress levels.</description>
        <time_frame>Subjects rated stress immediately following the second of two MRI scans on Day 3 of 3.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MRI 2 Women Oxytocin</title>
            <description>Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing the second of two MRI scans.
Oxytocin: intranasal administration, 40 IUs</description>
          </group>
          <group group_id="O2">
            <title>MRI 2 Women Placebo</title>
            <description>Cocaine-dependent women received intranasal saline prior to completing the second of two MRI scans.
Saline: intranasal administration, 40 IUs</description>
          </group>
          <group group_id="O3">
            <title>MRI 2 Men Oxytocin</title>
            <description>Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing the second of two MRI scans.
Oxytocin: intranasal administration, 40 IUs</description>
          </group>
          <group group_id="O4">
            <title>MRI 2 Men Placebo</title>
            <description>Cocaine-dependent men received intranasal saline prior to completing the second of two MRI scans.
Saline: intranasal administration, 40 IUs</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Stress Response MRI 2</title>
          <description>Subjects rated stress levels on a 0-10 Likert Scale where 0 is Not at All and 10 is Extremely so that lower scores indicate lower stress levels.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="1.67"/>
                    <measurement group_id="O2" value="1.83" spread="2.81"/>
                    <measurement group_id="O3" value="1.07" spread="2.07"/>
                    <measurement group_id="O4" value="1.39" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Cocaine Craving TSST</title>
        <description>Subjects rated craving on a 0-10 Likert Scale where 0 is Not at All and 10 is Extremely so that lower scores indicate lower craving.</description>
        <time_frame>Subjects rated craving immediately following a Social Stress task on Day 1 of 3.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TSST Women Oxytocin</title>
            <description>Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task.
Oxytocin: intranasal administration, 40 IUs</description>
          </group>
          <group group_id="O2">
            <title>TSST Women Placebo</title>
            <description>Cocaine-dependent women received intranasal saline prior to completing a Social Stress Task.
Saline: intranasal administration, 40 IUs</description>
          </group>
          <group group_id="O3">
            <title>TSST Men Oxytocin</title>
            <description>Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task.
Oxytocin: intranasal administration, 40 IUs</description>
          </group>
          <group group_id="O4">
            <title>TSST Men Placebo</title>
            <description>Cocaine-dependent men received intranasal saline prior to completing a Social Stress Task.
Saline: intranasal administration, 40 IUs</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Cocaine Craving TSST</title>
          <description>Subjects rated craving on a 0-10 Likert Scale where 0 is Not at All and 10 is Extremely so that lower scores indicate lower craving.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.08" spread="3.69"/>
                    <measurement group_id="O2" value="3.24" spread="3.38"/>
                    <measurement group_id="O3" value="3.45" spread="3.35"/>
                    <measurement group_id="O4" value="3.45" spread="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Cocaine Craving MRI 1</title>
        <description>Subjects rated craving on a 0-10 Likert Scale where 0 is Not at All and 10 is Extremely so that lower scores indicate lower craving.</description>
        <time_frame>Subjects rated craving immediately following the first of two MRI scans on Day 2 of 3.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MRI 1 Women Oxytocin</title>
            <description>Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing the first of two MRI scans.
Oxytocin: intranasal administration, 40 IUs</description>
          </group>
          <group group_id="O2">
            <title>MRI 1 Women Placebo</title>
            <description>Cocaine-dependent women received intranasal saline prior to completing the first of two MRI scans.
Saline: intranasal administration, 40 IUs</description>
          </group>
          <group group_id="O3">
            <title>MRI 1 Men Oxytocin</title>
            <description>Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing the first of two MRI scans.
Oxytocin: intranasal administration, 40 IUs</description>
          </group>
          <group group_id="O4">
            <title>MRI 1 Men Placebo</title>
            <description>Cocaine-dependent men received intranasal saline prior to completing the first of two MRI scans.
Saline: intranasal administration, 40 IUs</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Cocaine Craving MRI 1</title>
          <description>Subjects rated craving on a 0-10 Likert Scale where 0 is Not at All and 10 is Extremely so that lower scores indicate lower craving.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" spread="3.31"/>
                    <measurement group_id="O2" value="2.65" spread="2.81"/>
                    <measurement group_id="O3" value="3.04" spread="2.70"/>
                    <measurement group_id="O4" value="3.69" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Cocaine Craving MRI 2</title>
        <description>Subjects rated craving on a 0-10 Likert Scale where 0 is Not at All and 10 is Extremely so that lower scores indicate lower craving.</description>
        <time_frame>Subjects rated craving immediately following the second of two MRI scans on Day 3 of 3.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MRI 2 Women Oxytocin</title>
            <description>Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing the second of two MRI scans.
Oxytocin: intranasal administration, 40 IUs</description>
          </group>
          <group group_id="O2">
            <title>MRI 2 Women Placebo</title>
            <description>Cocaine-dependent women received intranasal saline prior to completing the second of two MRI scans.
Saline: intranasal administration, 40 IUs</description>
          </group>
          <group group_id="O3">
            <title>MRI 2 Men Oxytocin</title>
            <description>Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing the second of two MRI scans.
Oxytocin: intranasal administration, 40 IUs</description>
          </group>
          <group group_id="O4">
            <title>MRI 2 Men Placebo</title>
            <description>Cocaine-dependent men received intranasal saline prior to completing the second of two MRI scans.
Saline: intranasal administration, 40 IUs</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Cocaine Craving MRI 2</title>
          <description>Subjects rated craving on a 0-10 Likert Scale where 0 is Not at All and 10 is Extremely so that lower scores indicate lower craving.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="2.70"/>
                    <measurement group_id="O2" value="2.61" spread="2.78"/>
                    <measurement group_id="O3" value="2.04" spread="2.38"/>
                    <measurement group_id="O4" value="2.29" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from consent to the 1 month follow-up. That time period ranged from 6 weeks to 3 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TSST Women Oxytocin</title>
          <description>Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task.
Oxytocin: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="E2">
          <title>TSST Women Placebo</title>
          <description>Cocaine-dependent women received intranasal saline prior to completing a Social Stress Task.
Saline: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="E3">
          <title>MRI 1 Women Oxytocin</title>
          <description>Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing the first of two fMRI cue-exposure tasks.
Oxytocin: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="E4">
          <title>MRI 1 Women Placebo</title>
          <description>Cocaine-dependent women received intranasal saline prior to completing the first of two fMRI cue-exposure tasks.
Saline: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="E5">
          <title>MRI 2 Women Oxytocin</title>
          <description>Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing the second of two fMRI cue-exposure tasks.
Oxytocin: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="E6">
          <title>MRI 2 Women Placebo</title>
          <description>Cocaine-dependent women received intranasal saline prior to completing the second of two fMRI cue-exposure tasks.
Saline: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="E7">
          <title>TSST Men Oxytocin</title>
          <description>Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task.
Oxytocin: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="E8">
          <title>TSST Men Placebo</title>
          <description>Cocaine-dependent men received intranasal saline prior to completing a Social Stress Task.
Saline: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="E9">
          <title>MRI I Men Oxytocin</title>
          <description>Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing the first of two fMRI cue-exposure tasks.
Oxytocin: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="E10">
          <title>MRI I Men Placebo</title>
          <description>Cocaine-dependent men received intranasal saline prior to completing the first of two fMRI cue-exposure tasks.
Saline: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="E11">
          <title>MRI 2 Men Oxytocin</title>
          <description>Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing the second of two fMRI cue-exposure tasks.
Oxytocin: intranasal administration, 40 IUs</description>
        </group>
        <group group_id="E12">
          <title>MRI 2 Men Placebo</title>
          <description>Cocaine-dependent men received intranasal saline prior to completing the second of two fMRI cue-exposure tasks.
Saline: intranasal administration, 40 IUs</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lisa Nunn</name_or_title>
      <organization>MUSC</organization>
      <phone>843-792-0476</phone>
      <email>jenkinli@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

